文献速递中药与中成药合理使用

含四种常见毒性成分中成药综合安全性评价的风险-获益评估:临床风险因素分析

'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors.
PubMed 文献 · Front Pharmacol · 2024-08-23

该研究以2020版《中国药典》为据建立「毒性中药-毒性成分-中成药」数据库,统计含毒性成分中成药,筛选临床研究提取药品相关不良事件并分析特征与关联,总结不良反应原因并提取主要风险因素,为合理临床使用提供参考。

要点

  • 含毒性成分中成药主要有四类:含双酯型乌头碱代谢物、矿物成分、天南星科代谢物及氢氰酸。
  • 相关不良事件主要涉及消化系统、皮肤及其附属器及过敏反应。
  • 临床使用主要风险因素包括药物、用药、个体及监管四方面。

核心结论

  • 应用风险-获益评估方法可评价含毒性成分中成药的安全性,并建立「毒性成分-毒性中药-不良反应」数据库以探索其关系。

研究设计与样本

  • 研究基于2020版《中国药典》建立「毒性中药-毒性成分-中成药」数据库并统计含毒性成分中成药,筛选临床研究提取药品相关不良事件并分析特征与关联。

主要发现

  • 含毒性成分中成药主要有四类:含双酯型乌头碱代谢物、矿物成分、天南星科代谢物及氢氰酸。
  • 消化系统、皮肤及其附属器及过敏反应是四类含毒性成分中成药相关不良事件的主要类型。
  • 含毒性成分中成药临床使用的主要风险因素有药物、用药、个体及监管因素四类。

临床怎么用

  • 临床使用含毒性成分中成药时应关注消化系统、皮肤及过敏反应等不良事件,并综合评估药物、用药、个体及监管相关风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chinese patent medicines are specialty preparations in China that are produced using traditional prescriptions processed by modern pharmaceutical technology. They contain complex ingredients and much attention is paid to their clinical safety. Demonstrating the clinical safety of Chinese patent medicines containing toxic ingredients in modern pharmacological studies has become one of the urgent issues to be solved for the safe use of clinical medicines. OBJECTIVES: The aim of this research is to evaluate the safety of Chinese patent medicines containing toxic ingredients by applying the risk-benefit assessment method. Additionally, a database of 'toxic ingredients-toxic Chinese herbal medicines-adverse reactions' will be established to explore the relationship between toxic ingredients and adverse reactions. This will lay the foundation for the rational clinical use of Chinese patent medicines containing toxic ingredients. METHODS: 1) Establish a database of 'toxic Chinese herbal medicines-toxic ingredients-toxic Chinese patent medicines' to count the Chinese patent medicines containing toxic ingredients in the 2020 edition of Chinese Pharmacopoeia. 2) Filtered the clinical studies, extracted the drug-related ADEs, and analyzed the characteristics and correlations of these ADEs. 3) Finally, this section summarizes the causes of ADEs related to Chinese patent medicines containing toxic ingredients and extracts the main risk factors to provide a reference for further study. OUTCOMES: 1) There are four main types of Chinese patent medicines containing toxic ingredients. These include medicines with diester aconitine metabolites, mineral composition, Araceae metabolites, and hydrogen cyanide. 2) Digestive system, skin and its appendages, and allergic reactions were the main types of ADEs related to four types of Chinese patent medicines containing toxic ingredients. 3) There are four primary risk factors associated with the clinical use of Chinese patent medicines containing toxic ingredients: medicine, medication, individual and regulatory factors.

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Zhang N, Zhong C, Liu G, et al. 'Risk-benefit' assessment for comprehensive safety evaluation of Chinese patent medicines containing four common toxic ingredients: an analysis of clinical risk factors. Front Pharmacol. 2024. PMID: 39246661. doi:10.3389/fphar.2024.1324509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。